Loading stock…

Nurix Therapeutics, Inc. (NRIX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Nurix Therapeutics, Inc.

NRIXMarket cap $2.36BPrice $22.7

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops small-molecule drugs that harness the body's own protein-degradation machinery to destroy disease-causing proteins once considered "undruggable." Partnered with Gilead and Sanofi, Nurix bets its chemistry can outsmart cancer and autoimmune disease at the molecular level.

In Bastion Portfolios?

52W Return+131%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+30%10

Revenue Forecast

Rev CAGR (1y)+790%10

Rev CAGR (3y)+44%10

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-982%1

Net Income Margin-928%1

Free Cash Flow Margin-828%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-80%1

ROA-61%1

Earnings Stability22

GEAR+WEAK23

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)510

P/E Ratio (Forward 3y)na–

P/BV5.93

EV Multiples

EV/EBITDA Fwd510

EV/EBIT Fwd510

Yield

Free Cash Flow Yield-12.9%1

Dividend Yieldna–

Momentum

Short term

1 month return-13%2

3 month return-6%4

YTD return+20%8

Mid term

Price vs 52wHigh81%5

1 year return+128%10

Long term

3 year return+219%9

5 year return-18%3

Risk Shield

Price Risk

Beta1.32

Volatility57%2

Free Cash Flow

Free Cash Flow Margin-828%1

Free Cash Flow Yield-12.9%1

Quality

ROCE-74%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

NRIXNurix Therapeutics

Revenue FY25$84M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+790%10

Revenue, next 3Y, CAGR+44%10

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 44%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 30%/yr over the last 3 years and is set to grow 44%/yr from here.

WATCH

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-13%2

3-month return-6%4

YTD return+20%8

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+128%10

3-year return+219%9

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 128% over the past year, but 19% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+20%).

WATCH

Average long-term results. Multi-year returns are middling (+219% over three years and -18% over five), roughly average for the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming over the past month (-13%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Nurix Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NRIXNurix Therapeutics

Revenue FY25$84M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+790%10

Revenue, next 3Y, CAGR+44%10

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 44%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 30%/yr over the last 3 years and is set to grow 44%/yr from here.

WATCH

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-13%2

3-month return-6%4

YTD return+20%8

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+128%10

3-year return+219%9

5-year return-18%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 128% over the past year, but 19% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+20%).

WATCH

Average long-term results. Multi-year returns are middling (+219% over three years and -18% over five), roughly average for the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming over the past month (-13%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Nurix Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community